BUZZ-Vistagen cuts 20% of staff to extend cash runway, shares fall

Vistagen Therapeutics, Inc.

Vistagen Therapeutics, Inc.

VTGN

0.00

** Shares of drug developer Vistagen Therapeutics VTGN.O falls 3% to $0.60 premarket

** Co says it cut 20% of its workforce on March 5 to manage cash and support its Palisade program clinical studies

** Expects cash runway to now extend into 2027

** Palisade program includes studies of its experimental nasal spray for mental health conditions, aiming to offer faster-acting treatment options - VTGN

** Co says the job cuts will have immaterial costs and affected employees may receive cash severance and temporary healthcare coverage

** VTGN fell ~66% in 2025


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.